Reverting immune suppressionto elicit brain metastasis control

About us*

The RISEbrain consortium brings together the highly complementary expertise of 6 teams with inter-sectorial (basic and clinical) and interdisciplinary focus (life sciences, computational sciences, engineering) to tackle the growing societal challenge posed by brain metastases.

Learn more

Partners*

RISEbrain brings together 6 partners with diverse backgrounds and expertise. Learn more about our team on our website.

Meet the partners

Positions available*

We currently have job openings available! If you are interested check out our website for more information on how to apply.

See all

Consortium achievements*

At RISEBrain, each laboratory has achieved significant scientific achievements in their respective fields of study. Visit our website to learn more about our achievements and ongoing research.

See all
  • Marc Schmitz

Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer

J Immunother Cancer

  • Manuel Valiente

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. 

Monteiro, Miarka et al.
Nature Medicine

  • Manuel Valiente

STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis

Priego et al.
Nature Medicine (2018)

  • Marc Schmitz

Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T-cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia

Blood

  • Luca Bertero

Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.

Journal of Neuropathology & Experimental Neurology 2019 Mar 1;78(3):248-256

  • Luca Bertero

Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA.

Acta Neuropathologica 2019 May;137(5):837-846

News & Outreach*

Our RISEbrain partners have been published and featured in top media outlets and conferences. Learn more on our website.

See all

2023

  • Luca Bertero

Clinical studies

SILMET

A controlled, randomized, double-blind clinical trial to evaluate the efficacy of SILbinin versus placebo to prevent recurrence after surgical resection of a single brain METastasis from non-small cell lung carcinoma or breast carcinoma

2023

  • Marc Schmitz

Grants

SaxoCell: Development of theranostic target molecules for diagnosis and therapy

Funding Organisation: Federal Ministry of Education and Research

  • Serap Aksu

News

Nanotechnology: a portable device against cervical cancer

Read more

2023

  • Luca Bertero

Grant for internationalization

Molecular dissection of ovarian cancer brain metastasis microenvironment through spatial transcriptomics

Project partners: Pathology unit, Department of Medical Sciences, University of Turin, Italy and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK

Amount: 55.481,46€

10/2013

  • Hind Medyouf

Invited Speaker

European Macrophage and Dendritic cell society (EMDS) meeting

VIB Ghent, Belgium

06/2023

  • Hind Medyouf

Invited speaker

European Hematology Association Annual meeting

Frankfurt, Germany